Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

被引：0
|
作者：
Huyghe, N. [1 ]
Benidovskaya, E. [1 ]
Masoodi, T. [2 ]
Carrasco, J. [3 ]
De Cuyper, A. [4 ]
Sinapi, I. [3 ]
Vempalli, F. [2 ]
Verstraelen, E. [5 ]
Goffette, P. [5 ]
Ghaye, B. [5 ]
Papier, M.
Bedognetti, D. [2 ]
van Maanen, A. [5 ]
Castella, M-L. [5 ]
Galon, J. [6 ]
van den Eynde, M. [4 ]
机构：
[1] UCLouvain Univ Catholique Louvain, IIREC MIRO ONCO, Woluwe St Lambert, Belgium
[2] Sidra Med & Res Ctr, Al Rayyan, Qatar
[3] GHdC Grand Hop Charleroi Site Notre Dame, Med Oncol Dept, Charleroi, Belgium
[4] Clin Univ St Luc UCLouvain St Luc, Digest Oncol Dept, Woluwe St Lambert, Belgium
[5] Inst Roi Albert II Clin Univ St Luc, St Luc, Brussels, Belgium
[6] Cordeliers Res Ctr, Lab Integrat Canc Immunol, INSERM Team 15, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2237P
引用
收藏
页码：S1152 / S1152
页数：1
相关论文
共 50 条
  • [41] Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
    Haag, Georg Martin
    Halama, Niels
    Springfeld, Christoph
    Gruen, Barbara
    Apostolidis, Leonidas
    Zschaebitz, Stefanie
    Dietrich, Mareike
    Berger, Anne-Katrin
    Weber, Tim Frederik
    Zoernig, Inka
    Waberer, Lisa
    Mueller, Daniel Wilhelm
    Al-Batran, Salah-Eddin
    Jaeger, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts)
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Fioravanti, Anna
    Orlandi, Paola
    Salvatore, Lisa
    Canu, Bastianina
    Schirripa, Marta
    Masi, Gianluca
    Di Desidero, Teresa
    Marmorino, Federica
    Bergamo, Francesca
    Zoratto, Federica
    Bocci, Guido
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
    Altomare, I.
    Russell, K. B.
    Uronis, H. E.
    Morse, M.
    Hsu, S. D.
    Zafar, Y.
    Bendell, J. C.
    Starodub, A.
    Honeycutt, W.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)
    Stein, Alexander
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas Jens
    Doerfel, Steffen
    Al-Batran, Salah-Eddin
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [45] Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer
    Morris, Van K.
    Parseghian, Christine Megerdichian
    Escano, Michelle
    Johnson, Benny
    Raghav, Kanwal Pratap Singh
    Dasari, Arvind
    Huey, Ryan
    Overman, Michael J.
    Willis, Jason
    Lee, Michael Sangmin
    Wolff, Robert A.
    Kee, Bryan K.
    Shen, John Paul Y. C.
    Morelli, Maria Pia
    Tam, Alda
    Foo, Wai Chin
    Xiao, Lianchun
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO
    Cremolini, C.
    Antoniotti, C.
    Loupakis, F.
    Bergamo, F.
    Ferrari, L.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Solda, C.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) - Final Results of the phase II AVETUX trial (AIO-KRK-0216)
    Binder, Mascha
    Goekkurt, Eray
    Lorenzen, Sylvie
    Riera-Knorrenschild, Jorge
    Depenbusch, Reinhard
    Ettrich, Thomas
    Doerfel, Steffen
    Al-Batran, Salah
    Karthaus, Meinolf
    Pelzer, Uwe
    Simnica, Donjete
    Waberer, Lisa
    Hinke, Axel
    Bokemeyer, Carsten
    Hegewisch-Becker, Susanna
    Tintelnot, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Garattini, S. K.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Ruman, L.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Delliponti, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC).
    Sobrero, A
    Scheithauer, W
    Maurel, J
    Mineur, L
    Fehrenbacher, L
    Kisker, O
    Kopit, J
    Langer, C
    Schlichting, M
    Abubakr, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [50] Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
    Hubbard, Joleen M.
    Ahn, Daniel H.
    Jones, Jeremy Clifton
    Wittenberger, Kathleen
    Molnar, Levente
    Lorincz, Orsolya
    Somogyi, Eszter
    Csiszovszki, Zsolt
    Youssoufian, Hagop
    Toke, Eniko Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS283 - TPS283
12345